CAR T cell therapies have revolutionized outcomes for certain blood cancers, yet their impact on solid tumors has lagged. The field has long wrestled with T cell exhaustion—a state in which engineered cells lose their potency and fail to sustain an anti?tumor response.
At this year’s AACR annual meeting in San Diego, researchers from the Perelman School of Medicine at the University of Pennsylvania presented first?in?human Phase I data pointing to a possible solution. Their novel “KIR?CAR” T cell therapy demonstrated a favorable safety profile and early signals of activity across multiple solid tumor types.
The investigational therapy, SynKIR-110, represents a departure from traditional CAR T designs. Rather than using a single-chain receptor, the therapy is modeled after natural killer (NK) cell receptors and uses a “multi-chain” architecture.
This design separates tumor recognition from activation, effectively creating an intrinsic “on-off” mechanism. The T…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
